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A B S T R A C T
Background: Mass spectrometric-based measurements of the steroid metabolome have been introduced to
diagnose disorders featuring abnormal steroidogenesis. Defined reference intervals are important for interpret-
ing such data.
Methods: Liquid chromatography–tandem mass spectrometry was used to establish reference intervals for 16
steroids (pregnenolone, progesterone, 11-deoxycorticosterone, corticosterone, aldosterone, 18-oxocortisol, 18-
hydroxycortisol, 17-hydroxyprogesterone, 21-deoxycortisol, 11-deoxycortisol, cortisol, cortisone, dehydroepian-
drosterone, dehydroepiandrosterone-sulfate, androstenedione, testosterone) measured in plasma from 525
volunteers with (n = 227) and without (n = 298) hypertension, including 68 women on oral contraceptives.
Results: Women showed variable plasma concentrations of several steroids associated with menstrual cycle
phase, menopause and oral contraceptive use. Progesterone was higher in females than males, but most other
steroids were higher in males than females and almost all declined with advancing age. Using models that
corrected for age and gender, body mass index showed weak negative relationships with corticosterone, 21-
deoxycortisol, cortisol, cortisone, testosterone, progesterone, 17-hydroxyprogesterone and 11-deoxycorticoster-
one, but a positive relationship with 18-hydroxycortisol. Hypertensives and normotensives showed negligible
differences in plasma concentrations of steroids.
Conclusion: Age and gender are the most important variables for plasma steroid reference intervals, which have
been established here according to those variables for a panel of 16 steroids primarily useful for diagnosis and
subtyping of patients with endocrine hypertension.
1. Introduction
Liquid chromatography coupled to tandem mass spectrometry (LC-
MS/MS) for profiling of the steroid metabolome is increasingly showing
utility for investigations of a range of disorders of steroidogenesis
[1–7]. Apart from measurements of multiple steroids in a single sample
of a given matrix, LC-MS/MS offers advantages of more accurate
measurements than by immunoassays, which often suffer from antibody
cross reactivity resulting in higher than true concentrations [8–15].
Nevertheless, LC-MS/MS is not entirely free from interference so that
harmonization of methods, including agreement on reference intervals
remains important [16].
As with any new measurement method it is important to establish
reference intervals to enable identification of individuals within tested
patient populations who return abnormal results. Reference intervals
are usually established from the 95% confidence intervals or 97.5
percentiles of an appropriately sized and characterized reference
population [17]. Reference intervals for steroids established by im-
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munoassays are unlikely to be valid for LC-MS/MS-based assays and
there remains a general lack of published reference intervals for LC-MS/
MS measurements; those that are available mostly involve mass
spectrometric measurements of sex steroids, particularly in pediatric
populations where clinical relevance and demand is high [10,18–23].
Since LC-MS/MS adrenal steroid profiling directed to endocrine forms
of hypertension is in its infancy, reports that cover reference intervals
for LC-MS/MS measurements of steroids directed to primary aldoster-
onism or Cushing's syndrome mostly involve single steroids or limited
numbers of steroids in a panel [11,15,24–27].
Relative lack of commercial calibrators and quality control materi-
als for LC-MS/MS multi-steroid profiling methods confounds harmoni-
zation of laboratory results and establishment of reliable reference
intervals. Other considerations include biological and preanalytical
influences that can affect measured steroid concentrations. Influences
of age, gender, diurnal rhythms, physical or mental stress, energy
status, sampling position, pubertal stage, menstrual cycle and medica-
tions may all have variable impact on sex and adrenal steroids [28]. For
the adrenal steroids most useful for diagnosis or subtyping of patients
with Cushing's syndrome or primary aldosteronism it is also important
to establish whether measurements vary as a function of differences in
blood pressure and body mass.
With the above considerations in mind the present report provides a
first description of reference intervals for a panel of 16 steroids
measured in plasma by an LC-MS/MS method primarily developed for
diagnosis and subtyping of patients with disorders of steroidogenesis
associated with endocrine hypertension. Subjects included 525 adult
volunteers with and without hypertension. All blood sampling was
carried out according to a standardized protocol to minimize variations
due to time of day, food intake, posture and physical or mental stress.
Requirements for age- and gender-specific reference intervals were
examined along with influences of oral contraceptive use, blood
pressure and body mass index that might confound test results in
patients with primary aldosteronism and Cushing's syndrome.
2. Materials and methods
2.1. Subjects
Subjects included 525 normotensive and hypertensive volunteers,
all providing written informed consent under a clinical protocol
approved by the local Ethics committee that allowed for collections
of data and banking of biological specimens for purposes of compar-
isons to patient populations and establishment of reference intervals for
new diagnostic tests. Enrolment of subjects was facilitated by adver-
tisement with a small financial reward to encourage involvement.
Subjects were aged 18 to 81 years (median 42) and included 293
females and 232 males, among whom 104 (35%) of the females and 123
(53%) of the males had hypertension (Table 1).
All subjects underwent a standard medical history and physical
examination that included recordings of prescribed and non-prescribed
medications and dietary supplements, body weight, height, heart rate
and office blood pressure, the latter recorded in triplicate. Presence of
hypertension was established by systolic blood pressure above or equal
to 140 mm Hg or diastolic blood pressure above or equal to 90 mm Hg
and further confirmed or excluded in 378 subjects by 24 h ambulatory
blood pressure monitoring (systolic blood pressure ≥ 130 and diastolic
blood pressure ≥ 80). Hypertension was also defined in patients with a
stated history of high blood pressure controlled by antihypertensive
medications.
Among female participants 68 were taking oral contraceptives
(Table 1) and 88 were identified as post-menopausal according to
age-related cessation of menstruation for at least one year. Among the
remaining 137 premenopausal women, 45 were identified to be in the
luteal phase and 30 in the follicular phase of the menstrual cycle at the
time of blood sampling. Subjects with serious medical conditions or
taking steroid hormones other than oral contraceptives were excluded
from the analysis.
2.2. Blood sampling
All blood sampling was carried out between 8:00–10:00 AM after an
overnight fast and refraining from caffeinated beverages in the morning
before sampling, which was carried out after 20 min or more of supine
rest. Heparinized blood samples were kept chilled and centrifuged
within 2 h of collection to separate plasma, which was stored at−80 °C
until assayed.
2.3. LC-MS/MS
LC-MS/MS was performed using a QTRAP 5500 triple quadrupole
mass spectrometer (AB Sciex, Darmstadt, Germany) coupled to an
Acquity® ultra performance liquid chromatography (UPLC) system
(Waters Corporation, Milford, MA, USA). The latter was equipped with
a binary solvent manager, a sample manager, a column manager, a
Phenomenex Kinetex C18 column (2.6 μm, 2.1 × 100 mm) and guard
column (Phenomenex.). The method for analysis of the plasma steroid
panel, including validation and assay performance characteristics has
been described in detail elsewhere [29]. In brief, sample preparation
involved solid phase extraction utilizing OASIS® HLB-96 well plates and
a Positive-Pressure-96 Processor (all from Waters Corp.). Eluants were
dried down and reconstituted in mobile phase for injection on to the LC-
MS/MS system.
The steroids in the panel included pregnenolone, progesterone, 11-
deoxycorticosterone, corticosterone, aldosterone, 18-oxocortisol, 18-
hydroxycortisol, 17-hydroxyprogesterone, 21-deoxycortisol, 11-deoxy-
cortisol, cortisol, cortisone, dehydroepiandrosterone (DHEA), dehy-
droepiandrosterone-sulfate (DHEA-SO4), androstenedione and testos-
terone. Over the time course of the study inter-assay coefficients of
variation ranged from 3.3% to 11.8% for steroids in low to normal
ranges and 5.1% to 10.0% for those in high ranges. Participation in an
inter-laboratory quality assurance program (performed by the
Reference Institute for Bioanalytics, Bonn, Germany) involving mea-
surements of six steroids in the panel (cortisol, aldosterone, progester-
one, 17-hydroxyprogesterone, DHEA-SO4 and testosterone) among
different European laboratories indicated measurements within limits
of precision and accuracy for all six steroids.
2.4. Data analyses
The Kruskal-Wallis and the Steel Dwass all pairs methods were used
for non-parametric comparisons of women in different phases of the
menstrual cycle and compared to those taking oral contraceptives or of
post-menopausal status. Comparisons of men with women were carried
out using the Wilcoxon test, with exclusion of women taking oral
contraceptives where this was established to significantly impact
plasma concentrations of steroids. Influences or associations of gender,
age, body mass index, blood pressure status and oral contraceptive use
were examined by stepwise regression and least squares multivariate
analyses. Spearman's rank correlation coefficients were used to assess
Table 1
Demographic data for the 525 normotensive and hypertensive volunteers.
Gender N Age BMI Hypertension
Males 232 42 (18–81) 26 (19–49) 53% (123/232)
Females 293 42 (18–77) 24 (17–50) 35% (104/293)
No oral contraceptives 225 46 (19–77) 24 (17–50) 40% (89/225)
Oral contraceptives 68 26 (18–49) 23 (18–44) 22% (15/68)
Data for age (years) and body mass index (kg/m2) are shown as medians and ranges in
parentheses.
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significance of relationships. The above statistical analyses utilized the
JMP statistics software package (SAS Institute Inc., Cary, NC).
Age-specific reference intervals for steroids showing highly signifi-
cant impacts of age were established by multivariate fractional poly-
nomial analyses [30–32]. To derive equations for age-specific reference
intervals plasma concentrations were first normalized by logarithmic,
square root or x2 transformation, with age transformed in all cases




Following normalization, steroid concentrations were grouped
according to age. Average values and standard deviations of the groups
were then used for an independent fitting of polynomial models, which
allowed estimation of best-fit polynomial coefficients [33]. Reference
curves of the nth percentile of each steroid were then calculated









where Φ−1 is the inverse of the standard normal distribution, Mn(Age)
is the mean and SDn(Age) the standard deviation of the age groups. Due
to the fact that both age and yn are transformed and must be reversed to
the original scale, the formulae produced by the method become overly
complex. To simplify, we calculated the 2.5% and 97.5% percentiles for
all patients according to the estimated yn functions and subsequently
fitted a regression line to the derived percentile values, which were
then used as the reference interval curves. Fractional polynomial
analysis was conducted using R Studio version 0.99.082–2016 (R
version 3.2.1, R Core Team, 2013, http://www.r-project.org/). Curve
fitting of percentile equations was carried out and percentile plots were
prepared using the Matlab Curve fitting toolbox (3.5.1 2015) in Matlab
(version R2015a).
3. Results
3.1. Menstrual cycle, menopause and oral contraceptive use
Women not taking oral contraceptives and identified to be in the
luteal phase of the menstrual cycle had 24-fold higher (P < 0.0001)
plasma concentrations of progesterone and 3-fold higher (P < 0.0001)
concentrations of 17-hydroxyprogesterone than women in the follicular
phase of the menstrual cycle (Table 2). Apart from this there were no
clear differences in any of the other steroids according to luteal and
follicular phases.
Older post-menopausal women had 37% to 62% lower
(P < 0.0001) plasma concentrations of pregnenolone, DHEA and
DHEA-SO4 compared to all younger groups of women, independent of
menstrual cycle phase and oral contraceptive use (Table 2). Similarly
plasma concentrations of androstenedione, aldosterone and cortisone
were also lower (P < 0.05) in postmenopausal women than in all other
groups, though differences were of only a small to moderate magnitude
(18% to 44%). Postmenopausal women also had 25 to 56% lower
(P < 0.005) plasma concentrations of cortisol, corticosterone, 18-
oxocortisol and testosterone, but for cortisol and testosterone these
differences were confined to women in the luteal phase or taking oral
contraceptives, while for 18-oxocortisol the difference was confined to
women in the former group. Progesterone, 17-hydroxyprogesterone and
11-deoxycorticosterone were 55% to 98% lower (P < 0.01) in post-
menopausal than younger women who were not taking oral contra-
ceptives.
Oral contraceptive use was associated with divergent influences on
different steroids (Table 1). Women taking oral contraceptives had 88%
higher (P < 0.0001) plasma concentrations of cortisol and 94% higher
(P < 0.0001) plasma concentrations of corticosterone compared to the
combined group of younger premenopausal women in all phases of the
menstrual cycle. In contrast, plasma concentrations of 11-deoxycorti-
costerone, pregnenolone, progesterone 17-hydroxyprogesterone and
androstenedione were respectively 60% (P < 0.0001), 24%
(P = 0.0102), 78% (P < 0.0001), 72% (P < 0.0001) and 25%
(P = 0.0040) lower in women taking oral contraceptives compared to
all premenopausal women not taking oral contraceptives. The above
differences remained significant (P < 0.0001) for cortisol, 11-deox-
corticosterone, pregnenolone, progesterone 17-hydroxyprogesterone
and androstenedione using a model that corrected for age. In contrast,
for corticosterone the difference was lost (P = 0.0602) indicating that
higher concentrations of this steroid in women taking oral contra-
ceptives reflected their younger age.
Table 2
Plasma concentrations (medians & ranges) for the 16 steroids in post-menopausal compared to pre-menopausal females, the latter according to oral contraceptive use and follicular versus
luteal phases of menstrual cycle.
Steroid Luteal Follicular Oral contraceptive Post-menopausal
N 45 30 68 88
Age 31 [18–49]⁎⁎,† 38 [19–49]⁎⁎,† 26 [18–49]⁎⁎ 57 [45–77]
Pregnenolone 8.40 [2.46–29.67]⁎⁎,† 7.85 [1.54–24.77]⁎⁎ 5.31 [0.32–19.53]⁎⁎ 3.16 [0.32–9.23]
Progesterone 13.23 [0.07–83.00]⁎⁎,†,§ 0.56 [0.06–18.64]⁎,† 0.25 [0.01–1.00] 0.25 [0.03–11.42]
17-Hydroxyprogesterone 2.99 [0.37–8.28]⁎⁎,†,§ 1.08 [0.36–4.99]⁎⁎,† 0.42 [0.11–2.00] 0.51 [0.19–3.12]
11-Deoxycorticosterone 0.27 [0.01–0.57]⁎⁎,† 0.19 [0.01–0.50]⁎ 0.07 [0.01–0.49] 0.07 [0.01–0.71]
Corticosterone 6.26 [1.88–36.1]⁎ 5.76 [2.0–87.2] 10.20 [1.2–146.6]⁎⁎ 4.39 [1.5–35.8]
Aldosterone 0.19 [0.03–0.88]⁎ 0.17 [0.02–0.65]⁎ 0.16 [0.01–2.23]⁎ 0.11 [0.01–0.67]
18-Oxocortisol 0.03 [0.00–0.09]⁎ 0.03 [0.00–0.09] 0.02 [0.00–0.09] 0.02 [0.00–0.13]
18-Hydroxycortisol 1.68 [0.61–3.33] 1.71 [0.36–5.15] 1.42 [0.44–6.18] 1.22 [0.05–5.34]
21-Deoxycortisol 0.02 [0.00–0.54] 0.04 [0.00–0.22] 0.04 [0.00–0.41] 0.03 [0.00–0.35]
11-Deoxycortisol 0.45 [0.15–3.81] 0.40 [0.12–1.52] 0.29 [0.08–3.20] 0.37 [0.11–5.25]
Cortisol 295 [150–822]⁎,† 297 [97–979]† 509 [178–1271]⁎⁎ 233 [124–698]
Cortisone 63.2 [34.4–92.1]⁎⁎ 55.1 [28.9–87.9]⁎ 63.0 [39.4–109.0]⁎⁎ 44.1 [24.7–75.2]
DHEA 13.8 [4.0–58.6]⁎⁎ 15.8 [3.5–41.3]⁎⁎ 11.2 [1.0–55.1]⁎⁎ 6.7 [1.4–24.0]
DHEA-S 4108 [1156–8217]⁎⁎ 3741 [1186–7728]⁎⁎ 3918 [1371–9523]⁎⁎ 2721 [367–12,435]
Androstenedione 4.19 [1.26–12.81]⁎⁎,† 3.10 [1.80–6.91]⁎⁎ 2.87 [1.13–16.58]⁎ 2.34 [1.13–9.46]
Testosterone 1.13 [0.27–2.18]⁎ 0.93 [0.42–1.92] 1.12 [0.34–3.81]⁎ 0.75 [0.24–2.75]
All values are shown as nmol/L. All differences according to the Steel-Dwass test for multiple comparisons.
⁎ P < 0.05 different from menopause.
⁎⁎ P < 0.0001 different from menopause.
† P < 0.005, different from oral contraceptive.
§ P < 0.005, luteal different from follicular.
G. Eisenhofer et al. Clinica Chimica Acta 470 (2017) 115–124
117
3.2. Gender
Plasma concentrations of pregnenolone, 11-deoxycorticosterone,
corticosterone and aldosterone did not differ between males and
females, whereas concentrations of progesterone were higher
(P < 0.0001) in females than males (Table 3). The difference for
progesterone reflected high concentrations in younger premenopausal
women, particularly those in the luteal phase of the menstrual cycle
(Table 2).
Plasma concentrations for all other steroids were higher in men than
women (Table 3), with the largest difference (P < 0.0001) observed
for testosterone, which showed no overlap between males and females.
Other steroids showing strong gender differences included 17-hydro-
xyprogesterone, 18-oxocortisol, 18-hydroxycortisol, 11-deoxycortisol
and DHEA-SO4, which were respectively 211%, 50%, 43%, 43% and
48% higher (P < 0.0001) in men than women. Steroids showing
smaller gender differences included 21-deoxycortisol, cortisol, corti-
sone, DHEA and androstenedione, which were 6% to 24% higher
(P < 0.05) in men than women.
3.3. Multivariate analysis of gender, age and body mass index
With multivariate stepwise regression and least squares analyses the
influences of gender on plasma concentrations of steroids were
confirmed along with additional influences of age and body mass index
(Table 4). Advancing age was associated with significant negative
relationships with all steroids except 21-deoxycortisol. Strongest nega-
tive relationships (P < 0.0001) were observed for pregnenolone
(rs = −0.633), DHEA (rs =−0.580), cortisone (rs =−0.473), 11-
deoxycorticosterone (rs = −0.353) androstenedione (rs = −0.351),
17-hydroxyprogesterone (rs = −0.344), corticosterone (rs
= −0.331) and DHEA-SO4 (rs = −0.311), with significance main-
tained in all cases for both men and women. Negative relationships with
age were weaker for cortisol (rs = −0.257), aldosterone
(rs = −0.244), 18-oxocortisol (rs = −0.208), progesterone
(rs = −0.116) and 18-hydroxycortisol (rs =−0.099), and not always
maintained for both genders. Weak negative relationships between age
and 11-deoxycortisol or testosterone were only apparent with multi-
variate models adjusting for age and body mass index.
Body mass index, which was positively associated with age
(rs = 0.269, P < 0.0001), showed negative relationships with several
steroids. These negative relationships with body mass index were
generally weaker after adjusting for age and gender, and then only
apparent for progesterone, 17-hydroxyprogesterone, 11-deoxcorticos-
terone, corticosterone, 21-deoxycortisol, cortisol, cortisone and testos-
terone (Table 4). In contrast, 18-hydroxycortisol showed a weak
positive relationship (rs = −0.162, P = 0.0044) with body mass index.
For testosterone, relationships with body mass index and age were
gender specific (Fig. 1). Testosterone was negatively related with body
mass index in males (rs = −0.360, P < 0.0001), but not in females. In
contrast, females showed a negative relationship of testosterone with
advancing age (rs = 0.232, P = 0.0005). For males the negative
relationship of testosterone with age was weaker and did not remain
significant after adjustment for body mass index.
3.4. Hypertensives vs normotensives
Presence of hypertension was positively associated with advancing
age (P < 0.0001), increased body mass index (P < 0.0001) and male
gender (P = 0.0021). Accounting for those variables, multivariate
analyses indicated slightly higher (P = 0.0103) plasma concentrations
17-hydroxyprogesterone in normotensives than hypertensive and no
differences for any of the other steroids except for 21-deoxycortisol,
which was slightly higher in hypertensives than normotensives
(Table 4). Office measurements of systolic blood pressure were also
higher in males than females (P < 0.0001) and showed positive
associations with age (P < 0.0001) and body mass index
(P < 0.0001), but no clear relationships with any of the 16 steroids.
3.5. Reference intervals
Most steroids showed skewed distributions necessitating construc-
tion of reference intervals using non-parametric assessments of 2.5 and
97.5 percentiles, or when estimated as a function of age using normal-
ization and curve fitting according to estimates of best-fit polynomial
coefficients and associated variables (see Data-in-brief). For some
steroids, in particular 21-deoxycortisol, 11-deoxycorticosterone and
18-oxocortisol, plasma concentrations were below detectable limits in
15%, 11% and 2% of patients respectively so that only upper cut-offs of
reference intervals could be established.
As expected, testosterone and progesterone were the two steroids
showing most need for gender-specific reference intervals (Table 3),
with the latter also requiring consideration of post-menopausal and pre-
menopausal menstrual cycle status (Table 2). Steroids such as 18-
hydroxycortisol, DHEA-SO4, 11-deoxycortisol, cortisone, androstene-
dione and DHEA showed higher 2.5 and 97.5 percentiles in males than
Table 3
Median plasma concentrations with 2.5 and 97.5 percentiles for the 16 steroids shown for both genders together (ALL) and separately for males and females.
Steroid ALL Males Females
Pregnenolonea 5.06 [1.21–21.33] 5.13 [1.45–22.88] 5.06 [1.01–20.86]
Progesteronea 0.28 [0.05–43.09] 0.27 [0.04–0.70]† 0.38 [0.07–54.84]
17-Hydroxyprogesteronea 1.84 [0.28–6.26] 2.46 [0.87–6.24]† 0.79 [0.24–6.84]
11-Deoxycorticosteronea 0.11 [< 0.49] 0.11 [< 0.54] 0.10 [< 0.47]
Corticosterone 5.54 [1.69–41.23] 5.77 [1.65–40.51] 5.20 [1.69–63.84]
Aldosterone 0.14 [0.02–0.62] 0.13 [0.01–0.45] 0.14 [0.02–0.67]
18-Oxocortisol 0.02 [< 0.09] 0.03 [< 0.10]† 0.02 [< 0.09]
18-Hydroxycortisol 1.67 [0.45–4.33] 2.02 [0.74–4.64]† 1.41 [0.41–3.40]
21-Deoxycortisol 0.032 [< 0.297] 0.036 [< 0.445]§ 0.029 [< 0.217]
11-Deoxycortisol 0.44 [0.12–2.18] 0.53 [0.13–2.58]† 0.37 [0.11–1.69]
Cortisola 264 [126–665] 283 [134–644]§ 247 [121–700]
Cortisone 53.0 [28.1–90.4] 54.7 [28.9–90.9]§ 51.8 [26.6–72.1]
DHEA 10.3 [1.9–40.5] 11.1 [2.5–46.7]§ 10.1 [1.7–38.3]
DHEA-SO4 4163 [914–9390] 5333 [917–10,021]† 3592 [850–7435]
Androstenedionea 3.21 [1.16–8.01] 3.33 [1.53–8.28]§ 3.04 [1.06–7.72]
Testosterone 6.34 [0.26–32.7] 16.9 [7.6–37.1]† 0.93 [0.31–2.29]
All values are shown as nmol/L. All differences according to the Wilcoxon's rank sum test.
a Excludes females on oral contraceptives.
† P < 0.0001 different from females.
§ P < 0.05 different from females.
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females that paralleled significant gender specific differences in plasma
concentrations (Table 3). Larger extended upward variances in females
than males, despite opposite or no significant overall differences in
plasma concentrations, were observed for cortisol and aldosterone
indicating respective 9% and 49% higher 97.5 percentiles for these
steroids in women than men (Table 3).
Clear relationships of age with plasma concentrations of pregneno-
lone, androstenedione, DHEA, DHEA-SO4, cortisone, corticosterone and
11-deoxycorticosterone indicated a striking need for age-specific re-
ference intervals for these seven steroids, with additional needs to
consider gender (Figs. 2 and 3). For some steroids (11-deoxycorticos-
terione and cortisone in both genders, 17-hydroxypgrogesterone and
androstenedione in males and corticosterone and pregnenolone in
females) there was evidence of peaks in plasma concentrations at 21
to 23 years of age, suggesting lower concentrations at ages younger
than 21 years.
According to curve fitting models, DHEA, pregnenolone and corti-
costerone, showed the largest age related falls in plasma concentrations
(Figs. 2 & 3). Upper cut-offs for plasma DHEA fell in both men and
women by 69.9% from 54.1 and 48.8 nmol/L in 22-year olds to 16.3
and 14.7 nmol/L in 70-year old men and women respectively (Fig. 2,
panels A & B). For pregnenolone, respective upper cut-offs in 22-year
old men and women were 30.8 and 28.9 and fell by 74% and 75% to 8.0
and 7.3 nmol/L in 70-year olds (Fig. 2, panels G &H). Upper cut-offs
estimated for corticosterone in 22-year old men and women were
respectively 46.0 and 114.1 nmol/L and fell by 60% and 89% to 18.2
and 12.4 nmol/L in 70-year olds (Fig. 3, panels A & B). Age-related falls
in upper cut-offs between 22- and 70-year olds for other steroids were
also generally steeper in women than men, showing respective falls of
40% and 31% for DHEA-SO4 (Fig. 2, panels C & D), 56% and 36% for
androstenedione (Fig. 2, panels E & F), 43% and 42% for 11-deoxycor-
ticosterone (Fig. 3, panels C & D) and 39% and 29% for cortisone
Table 4
Multivariate analysis of differences in plasma concentrations of steroids according to gender, age, body mass index (BMI) and presence of hypertension.
Steroid Gender Age BMI Hypertension
Pregnenolonea 0.0525 0.0001 −ve 0.1075 0.0796
Progesteronea 0.0001 F > M 0.0009 −ve 0.0148 −ve 0.7093
17-Hydroxyprogesteronea 0.0001 M > F 0.0001 −ve 0.0215 −ve 0.0105 N > H
11-Deoxycorticosteronea 0.5301 0.0001 −ve 0.0499 −ve 0.0754
Corticosterone 0.4615 0.0001 −ve 0.0001 −ve 0.6327
Aldosterone 0.1462 0.0001 −ve 0.1242 0.4770
18-Oxocortisol 0.0001 M > F 0.0001 −ve 0.0743 0.5192
18-Hydroxycortisol 0.0001 M > F 0.0030 −ve 0.0044 +ve 0.8773
21-Deoxycortisol 0.0197 M > F 0.2273 0.0001 −ve 0.0058 H > N
11-Deoxycortisol 0.0001 M > F 0.0253 −ve 0.6777 0.7137
Cortisola 0.0256 M > F 0.0001 −ve 0.0011 −ve 0.2700
Cortisone 0.0002 M > F 0.0001 −ve 0.0005 −ve 0.5256
DHEA 0.0001 M > F 0.0001 −ve 0.1227 0.4955
DHEA-S04 0.0001 M > F 0.0001 −ve 0.3884 0.9493
Androstenedionea 0.0292 M > F 0.0001 −ve 0.0524 0.3587
Testosterone 0.0001 M > F 0.0003 −ve 0.0075 −ve 0.6823
Data are shown as P-values and where significant (i.e., P < 0.05) differences are shown for gender as higher in females than males (F > M) or higher in males than females (M > F),
for age and BMI according to the negative (−ve) or positive (+ve) nature of relationships and for any differences between normotensives (N) and hypertensives (H). Data were
logarithmically transformed before analyses.
a Excludes patients on oral contraceptives.
Fig. 1. Distributions of plasma concentrations of testosterone according to body mass index and age for men (•) and women ( ). Note that testosterone concentrations are presented using
a logarithmic scale. Regression lines are shown for relationships that are significant (P < 0.05).
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(Fig. 3, panels E & F).
For 17-hydroxyprogesterone, a relationship with age requiring age-
specific reference intervals was present for males, whereas for females
there was need to consider post-menopausal and pre-menopausal status
(Fig. 3 panels G &H).
From the above analyses, the reference intervals outlined in the
formulae of Figs. 2 and 3, along with data in Tables 2 and 3, were
compiled for all 16 steroids into a single table (see Data-in-brief) that
accounted for gender and age influences as required for each steroid.





Fig. 2. Distributions of plasma concentrations of DHEA (A, B), DHEA-SO4 (C, D), androstenedione (E, F), and pregnenolone (G, H) according to age for males (• A, C, E & G) and females (▴
B, D, F &H). Note that DHEA-SO4 concentrations are shown in μmol/L compared to nmol/L for other steroids. Values for 97.5 and 2.5 percentiles are displayed as empty square dotted
lines (□□□), whereas best-fit curves for upper and lower cut-offs are displayed by dashed lines (– – –) according to the equations shown for age specific upper cut-offs (UC) and lower
cut-offs (LC).
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population size did not allow calculation of 2.5 and 97.5 percentiles
according to luteal and follicular phases of the menstrual cycle. Instead
data are provided as lowest and highest values for those two specific
groups.
4. Discussion
This study provides new data on distributions of plasma concentra-
tions of 16 steroids in normotensive and hypertensive subjects, clarify-
ing major steroid-specific impacts of gender and age, with minor
differences according to body mass index and negligible associations
with blood pressure status. The analysis also extends current knowledge
about the confounding influences of oral contraceptives, which in
addition to increasing plasma concentrations of total cortisol also
impact several other steroids in downward directions. Most importantly
the study establishes gender-specific reference intervals with additional
age-specific considerations for half of the 16 steroids in the panel.





Fig. 3. Distributions of plasma concentrations of corticosterone (A, B), 11-deoxycorticosterone (C, D), cortisone (E, F), and 17-hydroxyprogesterone (G, H) according to age for males (• A,
C, E & G) and females (▴ B, D, F &H). Note that corticosterone concentrations are displayed using a logarithmic scale compared to linear scales for the other steroids. Values for 97.5 and
2.5 percentiles are displayed as empty square dotted lines (□□□), whereas best-fit curves for upper and lower cut-offs are displayed by dashed lines (– – –) according to the equations
shown for age specific upper cut-offs (UC) and lower cut-offs (LC). For 17-hydroxyprogesterone, age specific references are shown for males, whereas for females reference intervals are
shown according pre- versus post-menopausal status.
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hydroxyprogesterone, cortisone, corticosterone and 11-deoxycorticos-
terone age-specific reference intervals are provided that can be
calculated according to equations established from curve fitting. As
expected for progesterone and 17-hydroxyprogesterone, there are
additional requirements to consider pre- and post-menopausal age
groups, including luteal and follicular phases in the former group.
Although reference intervals for commonly measured steroids, such
as cortisol and testosterone, are well established for both immunoassays
and LC-MS/MS measurements, for most of the other steroids reference
intervals are mainly derived from immunoassays or are not well
described by any method. Even where reference intervals have been
described by LC-MS/MS, it remains important to establish accuracy and
harmonization of methods. LC-MS/MS measurements are not immune
from interferences that can manifest in different forms including ion
suppression or enhancement, ionic cross talk, isobaric interferences and
in source transformations [16]. For the scores of steroids present in
biological fluids, some with identical mass charge ratios, isobaric
interferences can be a problem for LC-MS/MS measurements when
chromatographic separation of isobaric compounds is not achieved.
Selection of specific product ions for steroids is particularly difficult to
achieve in order to avoid isobaric interferences. Since commercial
sources of most of the scores of endogenous steroids are limited, testing
for such potential interferences is also problematic. Thus, even with the
extended chromatographic separation achieved by our established LC-
MS/MS method, interferences and biased measurements remain possi-
ble for some of the uncommonly measured steroids in the panel. As new
and improved LC-MS/MS methods featuring these steroids become
available it will be useful to cross validate reference intervals for those
steroids.
For the more commonly measured steroids in the panel, results
derived from participation in inter-laboratory quality assurance pro-
grams support accuracy of measurements and thus reliability of defined
reference intervals for those particular steroids. Thus, the reference
intervals described here for plasma cortisol and cortisone are similar to
those described by Kushnir and colleagues [24]. Similarly median levels
and reference intervals for cortisol are in reasonable agreement with
those of Fanelli et al. [11], who described an LC-MS/MS method for a
panel of 8 steroids. Median plasma concentrations and reference
intervals for men and pre- and post-menopausal women of that study
also showed generally good agreement for plasma testosterone, pro-
gesterone and 17-hydroxyprogesterone to the results of the present
study. For corticosterone, 11-deoxycortisol and DHEA median plasma
concentrations were measured 30% to 44% lower than in the study of
Fanelli et al. [11], but reference intervals generally overlapped with no
consistent difference. In contrast, median concentrations for androste-
nedione averaged 60% higher in the present study than in the earlier
study with parallel differences in reference intervals. Differences in ages
of subjects of the two studies may account for some but not all of the
aforementioned differences.
In another report involving LC-MS/MS measurements of DHEA,
androstenedione and testosterone by Kushnir et al. [34], median
concentrations and reference intervals showed good agreement to the
results of the present study for both DHEA and testosterone in both
males and females, but up to 50% lower values for androstenedione.
Among several LC-MS/MS methods described for plasma aldosterone
[13,15,26,35–37], two outlined adult upper cut-offs of 0.62 and
0.64 nmol/L [15,36] that are almost identical to those of the present
study for combined genders. Although others have described LC-MS/MS
methods to quantify 18-oxocortisol and 18-hydroxycortisol for subtyp-
ing patients with primary aldosteronism [38], there appear to be few or
no reports outlining reference intervals for these two steroids. The
former steroid is present in plasma at particularly low and difficult to
measure concentrations, so the reference intervals described here are
preliminary and require further validation. Similarly for 21-deoxycor-
tisol, plasma concentrations are low, often not detectable and the
reference intervals described here require further validation using more
sensitive measurements.
Estrogen-containing oral contraceptives are well established to
increase plasma concentrations of cortisol by increasing corticoster-
oid-binding globulin, resulting in increased total levels of cortisol
[39,40]. Oral contraceptives are also established to decrease plasma
concentrations of several steroids, such as progesterone, 17-hydroxy-
progesterone and androstenedione [19,22,39], as also confirmed here.
We also show that 11-deoxycorticosterone is reduced by oral contra-
ceptives. Oral contraceptive use is thus a major confounder for
interpretation of steroid profiles.
Apart from the expected gender-associated differences in androgens,
we also establish higher concentrations in males than females of most
other steroids, which translated to a need for gender-specific reference
intervals. In agreement with earlier work [11], for 17-hydroxyproges-
terone and progesterone, gender-specific reference intervals require
separate considerations for post-menopausal compared to higher and
variable plasma concentrations during luteal and follicular phases of
the menstrual cycle.
In addition to gender differences, negative relationships of plasma
concentrations of androgens with age are well established [41,42],
necessitating both gender and age-related reference intervals. In two
recent reports, one involving a large population of women [19] and the
other men [43], reference intervals for LC-MS/MS-based measurements
of androstenedione and DHEA-SO4 were described by reference curves
that agree closely with those described here. Pregnenolone has also
been established to display an age-associated negative relationship
[44], with distributions for men and women in line with those
described here. The present study extends the findings of these other
reports by showing negative relationships of age with many other
steroids, such as corticosterone and 11-deoxycorticosterone, for which
age-specific reference intervals are now also established according to
curve fitted equations. Negative relationships of advancing age with
several additional steroids, including cortisol and aldosterone, though
significant were relatively weak so that requirements of age-specific
reference intervals for those steroids appear less critical.
Negative relationships of advancing age with plasma concentrations
of steroids in adults contrasts with the situation in children where
plasma concentrations of many steroids (e.g., corticosterone, cortisone,
cortisol, androstenedione, 17-hydroxyprogesterone and DHEA) increase
with advancing age during childhood and through the teenage years
[10,20,21]. This is also inline with the present findings for many of the
same steroids, which showed evidence of peak concentrations at 21 to
23 years of age. Thus, it is important to appreciate the highly dynamic
nature of steroid profiles in both children and adults and that the
reference intervals established in the present study are applicable only
to adults over the age of 21 years.
Although disordered steroidogenesis is widely accepted to be
associated with obesity, metabolic syndrome and hypertension
[45,46], it is also clear that such associations are complex, involving
other regulatory systems and differences in metabolism and clearance
[47–49]. The relatively minimal and weak associations of measured
steroids with body mass index and hypertension are thus not unex-
pected given the evidence for associations involving tissue-specific
differences in metabolism and biological actions. The negative relation-
ship of testosterone with body mass index in men is nevertheless
consistent with other evidence that male obesity is associated with low
testosterone [50].
In summary, this study outlines gender and age-specific reference
intervals for LC-MS/MS-derived measurements of plasma concentra-
tions for 16 steroids in a panel designed primarily for investigation of
patients with endocrine forms of hypertension. For many of the
commonly measured steroids results agree with literature findings,
but for others there are as yet no other comparable published data and
further verification will be important. For this, comparisons to other LC-
MS/MS methods will be useful (see Data-in-brief). It also remains
important to consider preanalytical factors [28]. Diurnal variations are
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particularly important to consider for many of the steroids in the panel
[5], so that it must be appreciated that the results of the present study
apply only to samples collected in morning hours.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cca.2017.05.002.
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